T1 measurements identify extracellular volume expansion in a genotyped hypertrophic cardiomyopathy population with and without left ventricular hypertrophy

Table 1 CMR Metrics of Fibrosis and Serum PICP levels

	Control N=10	p-value* Control vs Preclinical	Preclinical HCM N=30	p-value* Preclinical vs Overt	Overt HCM N=37	p-value* Control vs Overt
ECV (range)	0.26 ± 0.01 (0.24-0.31)	<0.001	0.33 ± 0.01 (0.23-0.38)	<0.001	0.37 ± 0.01 (0.31-0.51)	<0.001
ECV, excluding LGE	0.26 ± 0.01	<0.001	0.33 ± 0.01	<0.001	0.37 ± 0.01	<0.001
LGE present, % (#yes / #no)	0% (0/10)		0% (0/29)		78.4% (29/8)
LGE, g	0	0.8	0	0.004	16.7 ± 4.9	0.003
LGE, % LV mass	0	0.7	0	0.0006	7.76 ± 1.96 (0.9-44.6%)	0.001
PICP, μg/L	63.08 ± 4.19	<0.001	83.81 ± 4.39	0.035	108.04 ± 9.81	<0.001

Data are presented as means adjusted for family relations and age ± standard error *p values <0.017 are statistically significant and adjusted for age and family relations ECV = extracellular volume; LGE = late gadolinium enhancement; PICP = carboxy-terminal propeptide of procollagen type I

ISSN: 1532-429X